Investing.comDoubao · 实盘不做把握 8/10不做原因:标的无直接敞口
北京时间·🕒 发布 04:08:37·⟳ 抓取 04:09:09 +32s·⚡ 决策 10-13 04:10:49 +1m40s·14.5 天前
ArriVent 旗下第二款 ADC 药物 ARR-002 卵巢/子宫内膜癌 I 期试验完成首例患者给药
临床极早期的常规程序性里程碑：首例患者给药不含任何人体安全性/疗效数据，IND clearance(2026-05-07)后市场已知其即将入组，无预期差；对 ArriVent 是无近期收入的第二梯队资产，对艾力斯更是 immaterial 的区域期权。同时 ArriVent 核心管线 firmonertinib 于 2026-10-06 出现重大 III 期更新导致单日 -47%，股价处明确下行通道，此消息不构成反转催化。
📄 原文Investing.com↗ 原文
ArriVent doses first patient in ARR-002 ovarian cancer trial
S&P 500 little changed, Dow and Nasdaq mixed ahead of bank earnings, CPI this week NEWTOWN SQUARE, Pa. - ArriVent BioPh…
不做 ArriVent BioPharma（AVBP.US）
I 期首例患者给药是 IND 获批后的常规、已预告程序性节点，无人体数据、无金额、无预期差，距收入数年；且公司核心资产 firmonertinib 刚于10月6日 III 期更新后暴跌47%、股价处下行通道，此消息不构成可交易催化，无正期望
不做 上海艾力斯（688578.SH）
仅为 ARR-002 大中华区区域被授权方，资产尚处 I 期、无近期业绩或现金流贡献，对其市值 immaterial，属无因果敞口的弱主题联动
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ARR-002 I 期首例给药只是临床前→I 期的常规推进，无数据、无金额、已被 IND 获批和 Q1 财报预告，短期不改变任何公司的盈利或估值；ArriVent 自身刚受核心资产 III 期利空重创，方向上无可交易 edge，回避。
消息传播链
- 公司宣布 ARR-002 I 期完成首例给药；Investing.com 为 AI 生成+编辑审核的转述稿，未见显著扩散市场反应:10月12日 RTH 收 16.46 美元(-1.61%)，盘后 16.50 美元(+0.24%)、盘后成交极清淡，市场基本无反应
关键理由
- I 期首例给药不产生销售也不验证疗效，ArriVent 保留的海外权益兑现至少在数年之后
- 该里程碑在 2026年5月 IND clearance 时即已被市场预期，本次无新增信息增量
主要风险
- 公司核心资产 firmonertinib 的 FURVENT III 期更新于10月6日引发 -47% 暴跌，存在尚未释放的后续利空，逆势做多风险高
- I 期早期若出现安全性信号将进一步打压平台估值
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-06 · 影响 invalidates
核心资产 III 期更新于10月6日导致单日 -47%，近5日 -42%、处52周高位下方54%，下行趋势明确，ARR-002 给药无法对冲该利空
检索:ArriVent firmonertinib FURVENT Phase 3 update October 2026 - 做多前查反向 · 来源 web · 影响 weakens
公开新闻未披露艾力斯协议的首付款/里程碑金额，无法量化近期现金或收入增量
检索:ARR-002 licensing Allist upfront milestone payment terms
先例如何影响了这次决策
对本次决策的影响:未改变结论：无数据的临床启动不提供交易 edge
方向:未做先例统计：I 期 first-patient-dosed 属程序性、无数据里程碑，biotech 对此类事件普遍无显著正向反应，结论不依赖先例幅度即可成立
涨幅量级:无高相似对齐样本，且本决策为 AVOID，不需校准涨跌幅
形态:无
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`arrivent allist pharmaceuticals arr-002 greater china licensing | arrivent arr-002 first patient dosed phase 1 ovarian endometrial adc | avbp arr-002 muc16 napi2b antibody-drug con`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 1,138 ms
{ - web_search 成功 doubao_search · 1,130 ms
豆包搜索结果（原始查询:ArriVent ARR-002 first patient dosed Phase 1 press release；API SearchType:web）
原文全文
展开原文 · 2,022 字
S&P 500 little changed, Dow and Nasdaq mixed ahead of bank earnings, CPI this week
NEWTOWN SQUARE, Pa. - ArriVent BioPharma (NASDAQ:AVBP) announced today that it dosed the first patient in a Phase 1 trial of ARR-002, an antibody-drug conjugate designed to treat ovarian and endometrial cancer.
The trial, designated NCT07755436, is evaluating ARR-002 in patients with advanced or metastatic ovarian or endometrial cancer. The drug is described as a dual-target tetravalent antibody-drug conjugate that targets both MUC16 and NaPi2b proteins.
ARR-002 represents the company’s second antibody-drug conjugate to enter clinical testing. The drug uses site-specific conjugation to vcMMAE at a drug-to-antibody ratio of 4.
"Both MUC16 and NaPi2b are highly over-expressed in ovarian and endometrial cancer, and the dual targeting approach of ARR-002 is designed to overcome a key limitation of single-target ADCs in solid tumors where target expression can be heterogenous and can limit effective payload delivery to all tumor cells," said Stuart Lutzker, President of Research and Development at ArriVent, according to a press release statement.
The Phase 1 trial will evaluate the safety, tolerability, efficacy, and pharmacokinetics of ARR-002 in the patient population.
In August 2026, ArriVent entered into an exclusive licensing agreement with Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize ARR-002 in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan. ArriVent retained rights for all other territories.
Preclinical data presented at AACR in 2026 showed that ARR-002 demonstrated improved in vitro and in vivo activity compared to bivalent antibody-drug conjugates.
ArriVent is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The company’s clinical pipeline includes programs in lung and gastrointestinal cancers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEWTOWN SQUARE, Pa. - ArriVent BioPharma (NASDAQ:AVBP) announced today that it dosed the first patient in a Phase 1 trial of ARR-002, an antibody-drug conjugate designed to treat ovarian and endometrial cancer.
The trial, designated NCT07755436, is evaluating ARR-002 in patients with advanced or metastatic ovarian or endometrial cancer. The drug is described as a dual-target tetravalent antibody-drug conjugate that targets both MUC16 and NaPi2b proteins.
ARR-002 represents the company’s second antibody-drug conjugate to enter clinical testing. The drug uses site-specific conjugation to vcMMAE at a drug-to-antibody ratio of 4.
"Both MUC16 and NaPi2b are highly over-expressed in ovarian and endometrial cancer, and the dual targeting approach of ARR-002 is designed to overcome a key limitation of single-target ADCs in solid tumors where target expression can be heterogenous and can limit effective payload delivery to all tumor cells," said Stuart Lutzker, President of Research and Development at ArriVent, according to a press release statement.
The Phase 1 trial will evaluate the safety, tolerability, efficacy, and pharmacokinetics of ARR-002 in the patient population.
In August 2026, ArriVent entered into an exclusive licensing agreement with Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize ARR-002 in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan. ArriVent retained rights for all other territories.
Preclinical data presented at AACR in 2026 showed that ARR-002 demonstrated improved in vitro and in vivo activity compared to bivalent antibody-drug conjugates.
ArriVent is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The company’s clinical pipeline includes programs in lung and gastrointestinal cancers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
abca684fc1· 2026-10-13 04:10 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前